Will JAK1/2 inhibitors change the standard of care for myelofibrosis?

Abstract

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. http://dx.doi.org/10.5045/kjh.2012.47.4.241 The Korean Journal of Hematology Volume 47ᆞNumber 4ᆞDecember 2012